{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:29:25Z","timestamp":1789082965153,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100015086","name":"AOP Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015086","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                <jats:title>Abstract<\/jats:title>\n                <jats:p>Interferon-based therapies, such as ropeginterferon alfa-2b have emerged as promising disease-modifying agents for myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). Current ET treatments aim to normalize hematological parameters and reduce the thrombotic risk, but they do not modify the natural history of the disease and hence, have no impact on disease progression. Ropeginterferon alfa-2b (trade name BESREMi\u00ae), a novel, monopegylated interferon alfa-2b with an extended administration interval, has demonstrated a robust and sustained efficacy in polycythemia vera (PV) patients. Given the similarities in disease pathophysiology and treatment goals, ropeginterferon alfa-2b holds promise as a treatment option for ET. The ROP-ET trial is a prospective, multicenter, single-arm phase III study that includes patients with ET who are intolerant or resistant to, and\/or are ineligible for current therapies, such as hydroxyurea (HU), anagrelide (ANA), busulfan (BUS) and pipobroman, leaving these patients with limited treatment options. The primary endpoint is a composite response of hematologic parameters and disease-related symptoms, according to modified European LeukemiaNet (ELN) criteria. Secondary endpoints include improvements in symptoms and quality of life, molecular response and the safety profile of ropeginterferon alfa-2b. Over a 3-year period the trial assesses longer term outcomes, particularly the effects on allele burden and clinical outcomes, such as disease-related symptoms, vascular events and disease progression. No prospective clinical trial data exist for ropeginterferon alfa-2b in the planned ET study population and this study will provide new findings that may contribute to advancing the treatment landscape for ET patients with limited alternatives.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>EU Clinical Trials Register; EudraCT, 2023-505160-12-00; Registered on October 30, 2023.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00277-024-05665-4","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T20:01:51Z","timestamp":1709582511000},"page":"2299-2310","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options"],"prefix":"10.1007","volume":"103","author":[{"given":"Jean-Jacques","family":"Kiladjian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca Ferrer","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifa Kathrin","family":"Al-Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Alvarez-Larr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloise","family":"Beggiato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bieniaszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Buxhofer-Ausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Cerna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Manuela","family":"Crisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalin Doru","family":"Danaila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstanze","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Empson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Gora-Tybor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Griesshammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Grosicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Garc\u00eda-Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian H.","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arp\u00e1d","family":"Ill\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciprian","family":"Tomuleasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Theresa","family":"Krauth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Krejcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela-Cornelia","family":"Lazaroiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt Gy\u00f6rgy","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck-Emmanuel","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Pappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas Johannes","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Sacha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Schlager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Unger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"W\u00f6lfler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca Xicoy","family":"Cirici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Klade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"issue":"8","key":"5665_CR1","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","volume":"112","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian JJ, Cassinat B, Chevret S et al (2008) Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112(8):3065\u20133072. https:\/\/doi.org\/10.1182\/blood-2008-03-143537","journal-title":"Blood"},{"issue":"4","key":"5665_CR2","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1016\/S2352-3026(17)30030-3","volume":"4","author":"L Masarova","year":"2017","unstructured":"Masarova L, Patel KP, Newberry KJ et al (2017) Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol 4(4):e165\u2013e175. https:\/\/doi.org\/10.1016\/S2352-3026(17)30030-3","journal-title":"Lancet Haematol"},{"issue":"no Suppl 1","key":"5665_CR3","doi-asserted-by":"publisher","first-page":"pp580","DOI":"10.1182\/blood-2018-99-111255","volume":"132","author":"TA Knudsen","year":"2018","unstructured":"Knudsen TA, Hansen DL, Ocias LF et al (2018) Long-term efficacy and safety of recombinant interferon alpha-2 vs. hydroxyurea in polycythemia vera: preliminary results from the three-year analysis of the Daliah Trial - a randomized controlled phase III clinical trial. Blood 132(no Suppl 1):pp580. https:\/\/doi.org\/10.1182\/blood-2018-99-111255","journal-title":"Blood"},{"issue":"18","key":"5665_CR4","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1182\/blood.2019000428","volume":"134","author":"A Yacoub","year":"2019","unstructured":"Yacoub A, Mascarenhas J, Kosiorek H et al (2019) Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood 134(18):1498\u20131509. https:\/\/doi.org\/10.1182\/blood.2019000428","journal-title":"Blood"},{"issue":"3","key":"5665_CR5","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P et al (2020) Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol 7(3):e196\u2013e208. https:\/\/doi.org\/10.1016\/S2352-3026(19)30236-4","journal-title":"Lancet Haematol"},{"issue":"19","key":"5665_CR6","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1182\/blood.2021012743","volume":"139","author":"J Mascarenhas","year":"2022","unstructured":"Mascarenhas J, Kosiorek HE, Prchal JT et al (2022) A randomized phase 3 trial of interferon-alpha vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood 139(19):2931\u20132941. https:\/\/doi.org\/10.1182\/blood.2021012743","journal-title":"Blood"},{"key":"5665_CR7","doi-asserted-by":"publisher","unstructured":"Barbui T, Vannucchi AM, De Stefano V et al (2023) Ropeginterferon versus standard therapy for low-risk patients with polycythemia vera. NEJM Evid 2(6). https:\/\/doi.org\/10.1056\/EVIDoa2200335","DOI":"10.1056\/EVIDoa2200335"},{"key":"5665_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02008-6","author":"H Gisslinger","year":"2023","unstructured":"Gisslinger H, Klade C, Georgiev P et al (2023) Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment. Leukemia. https:\/\/doi.org\/10.1038\/s41375-023-02008-6","journal-title":"Leukemia"},{"issue":"5","key":"5665_CR9","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","volume":"36","author":"JJ Kiladjian","year":"2022","unstructured":"Kiladjian JJ, Klade C, Georgiev P et al (2022) Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. Leukemia 36(5):1408\u20131411. https:\/\/doi.org\/10.1038\/s41375-022-01528-x","journal-title":"Leukemia"},{"issue":"1","key":"5665_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00281-018-0700-2","volume":"41","author":"HC Hasselbalch","year":"2019","unstructured":"Hasselbalch HC, Holmstrom MO (2019) Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure? Semin Immunopathol 41(1):5\u201319. https:\/\/doi.org\/10.1007\/s00281-018-0700-2","journal-title":"Semin Immunopathol"},{"issue":"2","key":"5665_CR11","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41375-021-01447-3","volume":"36","author":"G Abu-Zeinah","year":"2021","unstructured":"Abu-Zeinah G, Silver RT, Abu-Zeinah K et al (2021) Normal life expectancy for polycythemia vera (PV) patients is possible. Leukemia 36(2):569\u2013572. https:\/\/doi.org\/10.1038\/s41375-021-01447-3","journal-title":"Leukemia"},{"issue":"16","key":"5665_CR12","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1182\/blood.2022017416","volume":"141","author":"J How","year":"2023","unstructured":"How J, Garcia JS, Mullally A (2023) Biology and therapeutic targeting of molecular mechanisms in MPNs. Blood 141(16):1922\u20131933. https:\/\/doi.org\/10.1182\/blood.2022017416","journal-title":"Blood"},{"issue":"10","key":"5665_CR13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-018-0133-0","volume":"8","author":"E Verger","year":"2018","unstructured":"Verger E, Soret-Dulphy J, Maslah N et al (2018) Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo. Blood Cancer J 8(10):94. https:\/\/doi.org\/10.1038\/s41408-018-0133-0","journal-title":"Blood Cancer J"},{"issue":"9","key":"5665_CR14","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.6004\/jnccn.2022.7026","volume":"20","author":"J How","year":"2022","unstructured":"How J, Hobbs G (2022) Interferons as the first choice of cytoreduction in essential thrombocythemia and polycythemia vera. J Natl Compr Canc Netw 20(9):1063\u20131068. https:\/\/doi.org\/10.6004\/jnccn.2022.7026","journal-title":"J Natl Compr Canc Netw"},{"issue":"16","key":"5665_CR15","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1182\/blood.2022017625","volume":"141","author":"AL Godfrey","year":"2023","unstructured":"Godfrey AL, Green AC, Harrison CN (2023) Essential thrombocythemia: challenges in clinical practice and future prospects. Blood 141(16):1943\u20131953. https:\/\/doi.org\/10.1182\/blood.2022017625","journal-title":"Blood"},{"issue":"2","key":"5665_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/14728214.2019.1615437","volume":"24","author":"L Masarova","year":"2019","unstructured":"Masarova L, Verstovsek S (2019) Emerging drugs for essential thrombocythemia. Expert Opin Emerg Drugs 24(2):93\u2013105. https:\/\/doi.org\/10.1080\/14728214.2019.1615437","journal-title":"Expert Opin Emerg Drugs"},{"issue":"1","key":"5665_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3324\/haematol.2017.174672","volume":"103","author":"G Birgegard","year":"2018","unstructured":"Birgegard G, Besses C, Griesshammer M et al (2018) Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the evaluation of anagrelide efficacy and long-term safety study. Haematologica 103(1):51\u201360. https:\/\/doi.org\/10.3324\/haematol.2017.174672","journal-title":"Haematologica"},{"issue":"10","key":"5665_CR18","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","volume":"121","author":"H Gisslinger","year":"2013","unstructured":"Gisslinger H, Gotic M, Holowiecki J et al (2013) Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 121(10):1720\u20131728. https:\/\/doi.org\/10.1182\/blood-2012-07-443770","journal-title":"Blood"},{"issue":"1","key":"5665_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41408-017-0041-8","volume":"8","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Vannucchi AM, Barbui T (2018) Essential thrombocythemia treatment algorithm 2018. Blood Cancer J 8(1):2. https:\/\/doi.org\/10.1038\/s41408-017-0041-8","journal-title":"Blood Cancer J"},{"issue":"12","key":"5665_CR20","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1007\/s00277-014-2152-7","volume":"93","author":"A Alvarez-Larran","year":"2014","unstructured":"Alvarez-Larran A, Martinez-Aviles L, Hernandez-Boluda JC et al (2014) Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Ann Hematol 93(12):2037\u20132043. https:\/\/doi.org\/10.1007\/s00277-014-2152-7","journal-title":"Ann Hematol"},{"issue":"1","key":"5665_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1365-2141.2010.08430.x","volume":"152","author":"JC Hernandez-Boluda","year":"2011","unstructured":"Hernandez-Boluda JC, Alvarez-Larran A, Gomez M et al (2011) Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance\/intolerance to hydroxycarbamide in essential thrombocythaemia. Br J Haematol 152(1):81\u201388. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08430.x","journal-title":"Br J Haematol"},{"issue":"5","key":"5665_CR22","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s11899-016-0335-0","volume":"11","author":"G Birgegard","year":"2016","unstructured":"Birgegard G (2016) The use of anagrelide in myeloproliferative neoplasms, with focus on essential thrombocythemia. Curr Hematol Malig Rep 11(5):348\u2013355. https:\/\/doi.org\/10.1007\/s11899-016-0335-0","journal-title":"Curr Hematol Malig Rep"},{"issue":"20","key":"5665_CR23","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"issue":"2","key":"5665_CR24","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/sj.leu.2404473","volume":"21","author":"G Barosi","year":"2007","unstructured":"Barosi G, Besses C, Birgegard G et al (2007) A unified definition of clinical resistance\/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia 21(2):277\u2013280. https:\/\/doi.org\/10.1038\/sj.leu.2404473","journal-title":"Leukemia"},{"issue":"23","key":"5665_CR25","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","volume":"121","author":"G Barosi","year":"2013","unstructured":"Barosi G, Mesa R, Finazzi G et al (2013) Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood 121(23):4778\u20134781. https:\/\/doi.org\/10.1182\/blood-2013-01-478891","journal-title":"Blood"},{"issue":"4","key":"5665_CR26","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s41375-023-01837-9","volume":"37","author":"F Stegelmann","year":"2023","unstructured":"Stegelmann F, Teichmann LL, Heidel FH et al (2023) Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-alpha: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN). Leukemia 37(4):924\u2013928. https:\/\/doi.org\/10.1038\/s41375-023-01837-9","journal-title":"Leukemia"},{"key":"5665_CR27","unstructured":"ICH Harmonised Tripartite Guideline (1999) Statistical principles for clinical trials, international conference on harmonisation E9 Expert Working Group Stat Med 18(15):1905\u20131942. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10532877"},{"issue":"Supplement 1","key":"5665_CR28","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.1182\/blood-2018-99-116852","volume":"132","author":"JA Gilreath","year":"2018","unstructured":"Gilreath JA, Tashi T, Kim SJ et al (2018) Compassionate use of ropeginterferon-alfa-2b\/P1101 for treatment of high risk polycythemia vera and essential thrombocythemia patients previously controlled on pegylated interferon-alfa-2a\/Pegasys\u00ae. Blood 132(Supplement 1):5459\u20135459. https:\/\/doi.org\/10.1182\/blood-2018-99-116852","journal-title":"Blood"},{"issue":"Supplement 1","key":"5665_CR29","doi-asserted-by":"publisher","first-page":"12284","DOI":"10.1182\/blood-2022-157076","volume":"140","author":"J How","year":"2022","unstructured":"How J, Hobbs G (2022) Real-world experience of ropeginterferon in myeloproliferative neoplasm patients. Blood 140(Supplement 1):12284\u201312285. https:\/\/doi.org\/10.1182\/blood-2022-157076","journal-title":"Blood"},{"issue":"2","key":"5665_CR30","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jfma.2020.08.021","volume":"120","author":"CE Huang","year":"2021","unstructured":"Huang CE, Wu YY, Hsu CC et al (2021) Real-world experience with ropeginterferon-alpha 2b (Besremi) in philadelphia-negative myeloproliferative neoplasms. J Formos Med Assoc 120(2):863\u2013873. https:\/\/doi.org\/10.1016\/j.jfma.2020.08.021","journal-title":"J Formos Med Assoc"},{"issue":"Suppl","key":"5665_CR31","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/01.HS9.0000852292.38263.b8","volume":"6","author":"W Novak","year":"2022","unstructured":"Novak W, Annam\u00e1ria C, Crazzolara R et al (2022) Severe complications in JAK2 V617F positive pediatric patients with myeloproliferative neoplasms. Hemasphere 6(Suppl):936\u2013937. https:\/\/doi.org\/10.1097\/01.HS9.0000852292.38263.b8","journal-title":"Hemasphere"},{"key":"5665_CR32","doi-asserted-by":"publisher","first-page":"100360","DOI":"10.1016\/j.lrr.2022.100360","volume":"19","author":"J Okikiolu","year":"2023","unstructured":"Okikiolu J, Woodley C, Cadman-Davies L et al (2023) Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys). Leuk Res Rep 19:100360. https:\/\/doi.org\/10.1016\/j.lrr.2022.100360","journal-title":"Leuk Res Rep"},{"issue":"4","key":"5665_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.48095\/cctahd2022prolekare.cz15","volume":"28","author":"N Podstavkov\u00e1","year":"2022","unstructured":"Podstavkov\u00e1 N, Weinbergerov\u00e1 B, Proch\u00e1zkov\u00e1 J et al (2022) Current experience with ropeginterferon Alfa-2b in Ph negative myeloproliferative neoplasm at the Department of Internal Medicine \u2013 Haematology and Oncology in Brno. Transfuze Hematol Dnes 28(4):1\u20136. https:\/\/doi.org\/10.48095\/cctahd2022prolekare.cz15","journal-title":"Transfuze Hematol Dnes"},{"issue":"Supplement 1","key":"5665_CR34","doi-asserted-by":"publisher","first-page":"6397","DOI":"10.1182\/blood-2023-191268","volume":"142","author":"T Tashi","year":"2023","unstructured":"Tashi T, Reeves BN, Kim SJ et al (2023) Real-world experience of ropeginterferon-alfa treatment of PV and ET - Two centers experience. Blood 142(Supplement 1):6397. https:\/\/doi.org\/10.1182\/blood-2023-191268","journal-title":"Blood"},{"issue":"5","key":"5665_CR35","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM et al (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32(5):1057\u20131069. https:\/\/doi.org\/10.1038\/s41375-018-0077-1","journal-title":"Leukemia"},{"issue":"9","key":"5665_CR36","doi-asserted-by":"publisher","first-page":"e658","DOI":"10.1016\/S2352-3026(21)00204-0","volume":"8","author":"A Alvarez-Larran","year":"2021","unstructured":"Alvarez-Larran A, Sant\u2019Antonio E, Harrison C et al (2021) Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. Lancet Haematol 8(9):e658\u2013e665. https:\/\/doi.org\/10.1016\/S2352-3026(21)00204-0","journal-title":"Lancet Haematol"},{"issue":"10","key":"5665_CR37","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.6004\/jnccn.2017.0157","volume":"15","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Jamieson C, Bhatia R et al (2017) NCCN guidelines insights: Myeloproliferative neoplasms, version 2.2018. J Natl Compr Canc Netw 15(10):1193\u20131207. https:\/\/doi.org\/10.6004\/jnccn.2017.0157","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"5665_CR38","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41375-020-01020-4","volume":"35","author":"JP Bewersdorf","year":"2021","unstructured":"Bewersdorf JP, Giri S, Wang R et al (2021) Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis. Leukemia 35(6):1643\u20131660. https:\/\/doi.org\/10.1038\/s41375-020-01020-4","journal-title":"Leukemia"},{"issue":"3","key":"5665_CR39","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s12185-021-03171-1","volume":"114","author":"W Gu","year":"2021","unstructured":"Gu W, Yang R, Xiao Z et al (2021) Clinical outcomes of interferon therapy for polycythemia vera and essential thrombocythemia: a systematic review and meta-analysis. Int J Hematol 114(3):342\u2013354. https:\/\/doi.org\/10.1007\/s12185-021-03171-1","journal-title":"Int J Hematol"},{"key":"5665_CR40","doi-asserted-by":"crossref","unstructured":"Beauverd Y, Ianotto J-C, Thaw KH et al (2023) Impact of cytoreductive drugs upon outcomes in a contemporary cohort of adolescent and young adults with essential thrombocythemia and polycythemia vera. Retrieved from https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper185108.html. Accessed 27 Nov 2023","DOI":"10.1182\/blood-2023-185108"},{"issue":"1","key":"5665_CR41","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00280-002-0533-4","volume":"51","author":"Y Alvarado","year":"2003","unstructured":"Alvarado Y, Cortes J, Verstovsek S et al (2003) Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol 51(1):81\u201386. https:\/\/doi.org\/10.1007\/s00280-002-0533-4","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"5665_CR42","first-page":"1333","volume":"90","author":"C Langer","year":"2005","unstructured":"Langer C, Lengfelder E, Thiele J et al (2005) Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. Haematologica 90(10):1333\u20131338","journal-title":"Haematologica"},{"issue":"24","key":"5665_CR43","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","volume":"126","author":"E Verger","year":"2015","unstructured":"Verger E, Cassinat B, Chauveau A et al (2015) Clinical and molecular response to interferon-alpha therapy in essential thrombocythemia patients with CALR mutations. Blood 126(24):2585\u20132591. https:\/\/doi.org\/10.1182\/blood-2015-07-659060","journal-title":"Blood"},{"issue":"10","key":"5665_CR44","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.3324\/haematol.2011.061390","volume":"97","author":"K Gowin","year":"2012","unstructured":"Gowin K, Thapaliya P, Samuelson J et al (2012) Experience with pegylated interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica 97(10):1570\u20131573. https:\/\/doi.org\/10.3324\/haematol.2011.061390","journal-title":"Haematologica"},{"key":"5665_CR45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.leukres.2017.01.006","volume":"54","author":"K Gowin","year":"2017","unstructured":"Gowin K, Jain T, Kosiorek H et al (2017) Pegylated interferon alpha \u2013\u20092a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial. Leuk Res 54:73\u201377. https:\/\/doi.org\/10.1016\/j.leukres.2017.01.006","journal-title":"Leuk Res"},{"issue":"9","key":"5665_CR46","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1002\/cncr.23018","volume":"110","author":"E Jabbour","year":"2007","unstructured":"Jabbour E, Kantarjian H, Cortes J et al (2007) PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer 110(9):2012\u20132018. https:\/\/doi.org\/10.1002\/cncr.23018","journal-title":"Cancer"},{"issue":"11","key":"5665_CR47","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1002\/cncr.21900","volume":"106","author":"J Samuelsson","year":"2006","unstructured":"Samuelsson J, Hasselbalch H, Bruserud O et al (2006) A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer 106(11):2397\u20132405. https:\/\/doi.org\/10.1002\/cncr.21900","journal-title":"Cancer"},{"issue":"27","key":"5665_CR48","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.2217\/fon-2022-0596","volume":"18","author":"S Verstovsek","year":"2022","unstructured":"Verstovsek S, Komatsu N, Gill H et al (2022) SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia. Future Oncol 18(27):2999\u20133009. https:\/\/doi.org\/10.2217\/fon-2022-0596","journal-title":"Future Oncol"},{"issue":"16","key":"5665_CR49","doi-asserted-by":"publisher","first-page":"TPS7088","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7088","volume":"41","author":"L Masarova","year":"2023","unstructured":"Masarova L, Mascarenhas J, Qin A et al (2023) EXCEED-ET: a single-arm multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft (P1101) in north American adults with essential thrombocythemia. J Clin Oncol 41(16):TPS7088\u2013TPS7088. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS7088","journal-title":"J Clin Oncol"},{"issue":"15","key":"5665_CR50","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","volume":"126","author":"H Gisslinger","year":"2015","unstructured":"Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V et al (2015) Ropeginterferon alfa-2b, a novel IFNalpha-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood 126(15):1762\u20131769. https:\/\/doi.org\/10.1182\/blood-2015-04-637280","journal-title":"Blood"},{"issue":"2","key":"5665_CR51","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12185-022-03341-9","volume":"116","author":"Y Edahiro","year":"2022","unstructured":"Edahiro Y, Ohishi K, Gotoh A et al (2022) Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study. Int J Hematol 116(2):215\u2013227. https:\/\/doi.org\/10.1007\/s12185-022-03341-9","journal-title":"Int J Hematol"},{"issue":"10","key":"5665_CR52","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1038\/s41375-020-0767-3","volume":"34","author":"F Ferrer-Marin","year":"2020","unstructured":"Ferrer-Marin F, Arroyo AB, Bellosillo B et al (2020) miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk. Leukemia 34(10):2648\u20132659. https:\/\/doi.org\/10.1038\/s41375-020-0767-3","journal-title":"Leukemia"},{"key":"5665_CR53","doi-asserted-by":"publisher","first-page":"102476","DOI":"10.1155\/2015\/102476","volume":"2015","author":"HC Hasselbalch","year":"2015","unstructured":"Hasselbalch HC, Bjorn ME (2015) MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediators Inflamm 2015:102476. https:\/\/doi.org\/10.1155\/2015\/102476","journal-title":"Mediators Inflamm"},{"key":"5665_CR54","doi-asserted-by":"publisher","unstructured":"Morales ML, Ferrer-Marin F (2023) Deepening our understanding of the factors affecting landscape of myeloproliferative neoplasms: what do we know about them? Cancers (Basel) 15(4). https:\/\/doi.org\/10.3390\/cancers15041348","DOI":"10.3390\/cancers15041348"},{"issue":"10","key":"5665_CR55","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1038\/s41375-019-0500-2","volume":"33","author":"A Guy","year":"2019","unstructured":"Guy A, Favre S, Labrouche-Colomer S et al (2019) High circulating levels of MPO-DNA are associated with thrombosis in patients with MPN. Leukemia 33(10):2544\u20132548. https:\/\/doi.org\/10.1038\/s41375-019-0500-2","journal-title":"Leukemia"},{"issue":"18","key":"5665_CR56","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1182\/bloodadvances.2020004061","volume":"5","author":"S Schmidt","year":"2021","unstructured":"Schmidt S, Daniliants D, Hiller E et al (2021) Increased levels of NETosis in myeloproliferative neoplasms are not linked to thrombotic events. Blood Adv 5(18):3515\u20133527. https:\/\/doi.org\/10.1182\/bloodadvances.2020004061","journal-title":"Blood Adv"},{"key":"5665_CR57","doi-asserted-by":"publisher","unstructured":"Ferrer-Marin F, Cuenca-Zamora EJ, Guijarro-Carrillo PJ et al (2021) Emerging role of neutrophils in the thrombosis of chronic myeloproliferative neoplasms. Int J Mol Sci 22(3). https:\/\/doi.org\/10.3390\/ijms22031143","DOI":"10.3390\/ijms22031143"},{"key":"5665_CR58","doi-asserted-by":"publisher","first-page":"38738","DOI":"10.1038\/srep38738","volume":"6","author":"CP Marin Oyarzun","year":"2016","unstructured":"Marin Oyarzun CP, Carestia A, Lev PR et al (2016) Neutrophil extracellular trap formation and circulating nucleosomes in patients with chronic myeloproliferative neoplasms. Sci Rep 6:38738. https:\/\/doi.org\/10.1038\/srep38738","journal-title":"Sci Rep"},{"key":"5665_CR59","doi-asserted-by":"publisher","unstructured":"Wolach O, Sellar RS, Martinod K et al (2018) Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med 10(436). https:\/\/doi.org\/10.1126\/scitranslmed.aan8292","DOI":"10.1126\/scitranslmed.aan8292"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05665-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05665-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05665-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T16:04:09Z","timestamp":1720109049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05665-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["5665"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05665-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,4]]},"assertion":[{"value":"12 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Protocol Version 3.0 dated 26 Sep 2023. The first subject was enrolled on 04 Dec 2023.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trial Status"}},{"value":"List of participating centers (Table ).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CK, KK, MU, SS, VE are employees of AOP Health.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}